ALLK

Insider Trades

Name	Value	Action	Price	Current Price
Radford Harlan BairdChief Financial Officer $88k87.1k shares SellJun 28, 2024 $1.01 --

Trade ALLK

About Allakos Inc.

Allakos Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic agents. These treatments are designed to target specific immunomodulatory receptors on immune effector cells, addressing a spectrum of allergic, inflammatory, and proliferative conditions. The company's flagship investigational product is lirentelimab (AK002), a monoclonal antibody. This compound is currently undergoing a pivotal Phase III clinical trial for eosinophilic gastritis and/or duodenitis. It is also being evaluated in a Phase II/III study for eosinophilic esophagitis, and a Phase II trial for atopic dermatitis and chronic spontaneous urticaria. Furthermore, Allakos is exploring lirentelimab (AK002) for potential use in mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. In parallel, their pipeline includes AK006, another candidate being developed to tackle various allergic and inflammatory diseases. Established in 2012, Allakos Inc. operates from its headquarters located in Redwood City, California.

CEO: Robert Alexander
IPO Date: Jul 19, 2018

Market Data

Open: $0.3291
High: $0.3291
Low: $0.3291
Volume: 1.3M
Avg Volume: 1.2M
52W High: $1.56
52W Low: $0.22

Valuation

Market Cap: $30M
Enterprise Value: $5.5M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-94M
Revenue: $0
Net Income: $-116M
Cash: $18M
Debt: $4.2M

Events

EarningsNov 4